Contact us

    MrMrsMsDr



    Collection and Use of Personal Information. *

    Deep Bio becomes first Korean cancer diagnostic AI company to win CES Innovation Award

    SEOUL, SOUTH KOREA, NOVEMBER 21, 2023 / PRNewswire/ – Won the CES Innovation Award for pioneering a new milestone in Korean cancer diagnosis AI solutions.

    Link to the Article 

    Deep Bio announced today that it has been awarded the CES Innovation Award as the first Korean cancer diagnosis A.I. company in CES 2024, the world’s largest electronics exhibition, to be held in Las Vegas, USA, in the upcoming January.

    The Consumer Technology Association (CTA) today announced the products and technologies that won CES Innovation Awards. Deep Bio won the Innovation Award in the Digital Healthcare category, the first time the A.I. diagnostic-aid software company helped detect meaningful findings among cancer patients.

    Deep Bio recognizes this award as an achievement that demonstrates its world-class technology in cancer diagnosis and prognosis and raises the profile of Korean cancer diagnosis A.I. companies.

    Deep Bio leverages its expertise in deep learning and cancer pathology to provide state-of-the-art in vitro diagnostic software (IVDs, SaMDs) that analyzes various cancers’ cancerous areas and severity to help medical professionals make more informed decisions. As such, Deep Bio’s DeepDx Prostate has a high precision of 99% sensitivity and 97% specificity.

    “Deep Bio has proven its technical excellence both internally and externally, winning the silver medal at the Edison Awards in the United States, which is called the ‘Oscar of Innovation’ in 2021 and was won by Tesla’s Elon Musk and Apple’s Steve Jobs, as well as the first place in 2019 at the CAMELYON16 Challenge, which evaluates image recognition technology,” said Kim Sun-woo, CEO of Deep Bio. “We will strive to improve the cancer diagnosis environment and provide cutting-edge cancer diagnosis AI solutions to medical professionals through generous investment in technology to overcome the biggest challenge of humanity, cancer.”

    Meanwhile, CES 2024 will be held at the Las Vegas Convention Center in the United States from January 9th to 12th, and Deep Bio’s award can be searched on the CES Innovation Awards website.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    About Deep Bio

    Deep Bio is an AI healthcare company focusing on deep learning to advance the field of cancer pathology. By developing cutting-edge in vitro diagnostic software (IVD SaMD), Deep Bio strives to provide pathologists and medical professionals with state-of-the-art diagnostic aids for more accurate cancer diagnosis and prognosis. Its main products include DeepDx Prostate, an AI software for prostate cancer analysis, which was the first in vitro diagnostic product to be approved by the Ministry of Food and Drug Safety in Korea. In 2019, the product won the Silver Award at the U.S. Edison Awards, which was won by Apple (2012) and Tesla (2014), and also won first place at the CAMELYON17 Challenge, a global AI digital pathology image analysis competition. In 2021, Deep Bio was recognized as one of the top 100 AI startups in Korea for the third year in a row, and has been recognized as a company that will lead the innovation of digital healthcare in the future.

    Deep Bio to Participate in the 9th Digital Pathology & AI Congress: EUROPE!

    No alternative text description for this image

    Exciting news! We’re delighted to announce our participation in the 9th Digital Pathology & AI Congress: EUROPE! 🎉 🔬#DPAIC2023

    At this upcoming conference, we look forward to engaging in stimulating discussions, acquiring priceless insights, and delving into the latest breakthroughs within the realms of digital pathology and artificial intelligence.

    Curious to learn how Deep Bio Inc. is empowering hashtag#pathologists? Visit our team at booth #32!

    Deep Bio Joins CancerX to Revolutionize Cancer Diagnosis and Prognosis with AI Expertise

    SEOUL, SOUTH KOREA, NOVEMBER 7, 2023 / PRNewswire/ – Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the groundbreaking CancerX initiative, a public-private partnership unveiled earlier this year as part of the White House Cancer Moonshot program. This strategic partnership marks a significant milestone in the company’s mission to transform the landscape of cancer diagnosis and prognosis.

    Link to the Article 

    Deep Bio has been at the forefront of innovation in healthcare technology, leveraging its in-house expertise in deep learning and cancer pathology to develop cutting-edge solutions for the medical community. The company’s vision is to revolutionize the way cancer is diagnosed and treated by providing pathologists with state-of-the-art In Vitro Diagnostic Software as a Medical Device (IVD SaMDs) powered by deep learning algorithms. These advanced tools are set to significantly enhance the accuracy and efficiency of cancer diagnosis, enabling healthcare professionals to make more informed treatment decisions.

    Given that cancer is one of the most pressing global health challenges, CancerX assembles like-minded organizations and experts to collaborate on pioneering innovative solutions that will accelerate progress in cancer research, diagnosis, and treatment. Deep Bio is thrilled to be a part of this ambitious endeavor and is committed to deploying its expertise and resources to advance the fight against cancer.

    Sun Woo Kim, CEO and founder of Deep Bio, expressed his enthusiasm for this collaboration, stating, “Joining the CancerX program is a testament to our dedication to improving the lives of cancer patients and healthcare professionals. Our mission has always been to harness the power of artificial intelligence to provide more accurate, efficient, and accessible cancer diagnostics. This partnership with CancerX will amplify our impact and help us realize this vision.”

    “Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we’re honored to partner with Deep Bio to achieve the ambitious goals of CancerX,” said Smit Patel, Associate Program Director at Digital Medicine Society (DiMe). “Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey.”

    CancerX is known for uniting visionary companies and experts in a collective effort to conquer cancer through innovation, research, and advanced technology. Deep Bio will work closely with other participants to propel groundbreaking projects and develop solutions that will have a lasting impact on the fight against cancer.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    About Deep Bio

    Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. With a focus on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis. By harnessing the power of artificial intelligence, Deep Bio is committed to improving cancer treatment decisions and patient outcomes.